SCHEMBL7044057

SCHEMBL7044057

COc1nn(-c2ccc(N)cc2C)c(=O)o1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABHD16A O95870 2/20 0.49
ABHD6 Q9BV23 1/20 0.48
MGLL Q99685 5/20 0.47
FAAH O00519 5/20 0.45
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
THRB P10828 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
NR4A1 P22736 2/20 0.38
GAA P10253 1/20 0.38
PTK2B Q14289 1/20 0.38
LPL P06858 1/20 0.37
LIPC P11150 1/20 0.37
LIPE Q05469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044246 0.85 ABHD16A (0.48) ABHD16AABHD6MGLLFAAHMEN1
SCHEMBL7043879 0.79 ABHD16A (0.65) ABHD16AABHD6MGLLFAAHALDH1A1
SCHEMBL7046228 0.78 ABHD16A (0.72) ABHD16AABHD6MGLLFAAHLPL
SCHEMBL7047523 0.76 MGLL (0.67) ABHD16AABHD6MGLLFAAHLIPC
SCHEMBL7043178 0.75 ABHD16A (0.59) ABHD16AABHD6MGLLFAAHMAPT
SCHEMBL7046507 0.75 ABHD16A (0.56) ABHD16AMGLLFAAHMEN1ALDH1A1
SCHEMBL11619464 0.72 ABHD16A (0.49) ABHD16AMGLLFAAHALDH1A1MAPT
SCHEMBL7043185 0.72 ABHD16A (0.49) ABHD16AMGLLFAAHALDH1A1KMT2A
SCHEMBL11623525 0.71 ABHD16A (0.51) ABHD16AMGLLFAAHLPLLIPC
SCHEMBL11020550 0.71 ABHD16A (0.45) ABHD16AABHD6MGLLFAAHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 ABHD16A 1922/4885ABHD6 866/4885MGLL 1542/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE ABHD16A 62/4885ABHD6 215/4885MGLL 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.